Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...

Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

We recently published an article titled Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential. In this ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by a common condition.

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

In a new study, Ozempic - a drug sold to help with obesity and diabetes - is attributed to helping this disease.

The company’s flagship product, Rezdiffra, has shown strong commercial performance since its FDA approval in March 2024, becoming the first approved therapy for F2-F3 MASH in the U.S. In the ...

CEO Bill Sibold highlighted the momentum of Rezdiffra’s US launch, reporting $137 million in net sales for Q1 2025, reflecting a 33% increase quarter-over-quarter despite typical Q1 industry ...

It offers Rezdiffra, which is a liver-directed thyroid hormone receptor beta agonist for treating MASH. Following its FDA approval in March 2024, Rezdiffra has shown a strong performance in ...

Madrigal Pharmaceuticals Inc (MDGL) reports a 33% increase in net sales and significant patient growth, while navigating ...